This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Ketamine Adverse Reaction

Evaluation of Ketamine as Sedative Agent in Endoscopic Retrograde Cholangiopancreatography (ERCP)

Sponsored by Universiti Kebangsaan Malaysia Medical Centre

About this trial

Last updated 5 years ago

Study ID

Hukm

Status

Recruiting

Type

Interventional

Phase

Phase 4

Placebo

No

Accepting

18-75 Years
16+ Years
All
All

Trial Timing

Ended 4 years ago

What is this trial about?

This is a study evaluating the usage of Ketamine as sedative agent in ERCP. The usage of Ketamine will be compared to the standard sedation in our center, which is Midazolam in combination with Pethidine as analgesia.

What are the participation requirements?

Yes

Inclusion Criteria

- Malaysian citizens of who is able to give valid consent

- Patient planned for ERCP (either emergency or elective)

No

Exclusion Criteria

- Known hypersensitivity towards Ketamine or Midazolam

- Patient refusal to participate or unable to give consent

- Increased intracranial pressure, acute stroke (<3 months), intracranial haemorrhage (<3 months)

- Uncontrolled hypertension (BP>160/100) and tachycardia (Heart rate >120)

- Acute myocardial infarction, acute coronary syndrome (<3 months)

- Tachyarrythmia

- Pregnancy

- IVDU or substance abuse patient

- Patient with history of hallucination

- Child's Pugh Class C

Locations

Location

Status

Recruiting